The TP53 Codon 72 Polymorphism and Risk of Sporadic Prostate Cancer among Iranian Patients

被引:0
作者
Babaei, Farhad [1 ]
Ahmadi, Seyed Ali [2 ]
Abiri, Ramin [3 ]
Rezaei, Farhad [1 ]
Naseri, Maryam [1 ]
Mahmoudi, Mahmoud [4 ]
Nategh, Rakhshande [1 ]
Mokhtari Azad, Talat [1 ]
机构
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[3] Kermanshah Univ Med Sci, Sch Med, Dept Microbiol, Kermanshah, Iran
[4] Univ Tehran Med Sci, Sch Publ Hlth, Dept Epidemiol & Biostat, Tehran, Iran
关键词
Sporadic prostate cancer; Benign prostate hyperplasia; TP53; codon; 72; polymorphism; HUMAN-PAPILLOMAVIRUS INFECTION; P53; CODON-72; GENE; MUTATIONS; VARIANTS; ASSOCIATION; PROGRESSION; CARCINOMA; MDM2;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: The TP53 gene is one of the most frequently mutated genes amongst human malignancies, particularly TP53 codon 72 polymorphism. Furthermore, an association between the TP53 codon 72 variants and prostate cancer has been reported in several studies. Although some studies have indicated an association between the TP53 Arg/Arg variant and an increased risk for prostate cancer, other studies have shown a positive correlation between the TP53 Pro/Pro genotype instead. Therefore, to clarify if this polymorphism is associated with an increased risk of prostate cancer in Iranian men, we conducted a case-control study of 40 sporadic prostate cancer patients and 80 benign prostate hyperplasia cases. Methods: The TP53 codon 72 was genotyped using an allele specific PCR. Results: A significant association between the TP53 codon 72 genotype and prostate cancer risk was found (OR = 6.8, 95% CI = [1.8-25.1], P = 0.005). However, the results of this study did not support an association between age, the Gleason score nor TP53 genotype at codon 72 in prostate cancer patients. Conclusions: TP53 codon 72 polymorphism may have a great impact in the development of prostate cancer.
引用
收藏
页码:453 / 459
页数:7
相关论文
共 37 条
  • [1] iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72 polymorphic p53
    Bergamaschi, Daniele
    Samuels, Yardena
    Sullivan, Alexandra
    Zvelebil, Marketa
    Breyssens, Hilde
    Bisso, Andrea
    Del Sal, Giannino
    Syed, Nelofer
    Smith, Paul
    Gasco, Milena
    Crook, Tim
    Lu, Xin
    [J]. NATURE GENETICS, 2006, 38 (10) : 1133 - 1141
  • [2] Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese
    Bin Xu
    Xu, Zheng
    Cheng, Gong
    Min, Zhi-Chao
    Mi, Yuanyuan
    Zhang, Zhi-zhong
    Tao, Jun
    Li, Peng-Chao
    Wang, Mei-Lin
    Tang, Jia-Lin
    Zhang, Zheng-Dong
    Zhang, Wei
    Wu, Hong-Fei
    Feng, Ning-Han
    Hua, Li-Xin
    [J]. CANCER GENETICS AND CYTOGENETICS, 2010, 202 (02) : 76 - 81
  • [3] RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases
    Casey, G
    Neville, PJ
    Plummer, SJ
    Xiang, Y
    Krumroy, LM
    Klein, EA
    Catalona, WJ
    Nupponen, N
    Carpten, JD
    Trent, JM
    Silverman, RH
    Witte, JS
    [J]. NATURE GENETICS, 2002, 32 (04) : 582 - 583
  • [4] TP53 and MDM2 gene polymorphisms and risk of hepatocellular carcinoma among Italian patients
    Di Vuolo, Valeria
    Buonaguro, Luigi
    Izzo, Francesco
    Losito, Simona
    Botti, Gerardo
    Buonaguro, Franco M.
    Tornesello, Maria Lina
    [J]. INFECTIOUS AGENTS AND CANCER, 2011, 6
  • [5] Prevalent mutations in prostate cancer
    Dong, JT
    [J]. JOURNAL OF CELLULAR BIOCHEMISTRY, 2006, 97 (03) : 433 - 447
  • [6] Downing Sean R, 2003, Can J Urol, V10, P1924
  • [7] The codon 72 polymorphic variants of p53 have markedly different apoptotic potential
    Dumont, P
    Leu, JIJ
    Della Pietra, AC
    George, DL
    Murphy, M
    [J]. NATURE GENETICS, 2003, 33 (03) : 357 - 365
  • [8] Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
    Ferlay, Jacques
    Shin, Hai-Rim
    Bray, Freddie
    Forman, David
    Mathers, Colin
    Parkin, Donald Maxwell
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) : 2893 - 2917
  • [9] Paraffin removal from tissue sections for digestion and PCR analysis
    Fredricks, DN
    Relman, DA
    [J]. BIOTECHNIQUES, 1999, 26 (02) : 198 - +
  • [10] Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas
    Galic, Vijaya
    Willner, Julia
    Wollan, Melissa
    Garg, Ruchi
    Garcia, Rochelle
    Goff, Barbara A.
    Gray, Heidi J.
    Swisher, Elizabeth M.
    [J]. GENES CHROMOSOMES & CANCER, 2007, 46 (03) : 239 - 247